[Article updated 2/21 with more details on inventory management.]
Originally published by our sister publication Infectious Disease Special Edition
The FDA announced a revision to the emergency use authorization (EUA) for nirmatrelvir+ritonavir (Paxlovid, Pfizer): Nirmatrelvir+ritonavir manufactured and labeled in accordance with the EUA currently in U.S. distribution will remain authorized for use through the labeled or extended expiration date, as applicable, or through March 8, 2024,